BCR-ABL1 kinase domain mutational analysis of CD34+ stem/progenitor cells in newly diagnosed CML patients by Next-Generation Sequencing
2014
Mutations in the BCR-ABL1 kinase domain (KD) represent one of
the most important causes of resistance to tyrosine kinase
inhibitors (TKIs) treatment in patients with chronic myeloid
leukemia (CML). The resistance-causing mutations are
hypothesized to expand directly from the stem and/or progenitor
cells and are present in CD341 cells significantly earlier than
they occur in bone marrow or peripheral blood. Thus, early
detection of these mutations is of great importance, since it
can affect the subsequent TKI therapy.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI